跳到正文
ECA GMP News·AI 评分61

欧洲 GMP 检查员谈持续工艺确认的计划、统计与报告期望

Ongoing/Continued Process Verification - The Perspective of an European GMP Inspector

AI 导读

欧洲 GMP 检查员 Franz Schönfeld 在 ECA 课程中阐述了他对持续工艺确认的期望,并提出其至少可在非无菌领域替代常规再验证。他强调应有一份获批的持续工艺确认计划,说明所考察的工艺、核查范围与频次,并随工艺知识、表现和生命周期中的渐进变更调整;统计方法已是监管期望之一,但产品质量回顾(PQR)出具较晚且以产品为对象,不能替代持续工艺确认。

正文 · 原文

With the introduction of a process validation life cycle, a new element came into play: ongoing/continued process verification. Although it has been known for at least 10 years, this stage still poses a challenge for the pharmaceutical industry. As part of an ECA course on this topic, Dr Franz Schönfeld, an European GMP inspector, presented his views on the matter. What does he expect?He began his presentation with the statement: Your validation is only as good as your last batch. Using an active ingredient synthesis as an example, he explained the entire process validation life cycle in the form of the PDAC cycle: Plan: Identification and control of potential causes of contamination Do: Validation of proven acceptable ranges' (traditional, hybrid or continuous) Check: Checking the results of the validation runs (report vs plan, deviations) Act: Accept or change the process (e.g. additional sampling)It was very important to Dr Schönfeld that anomalies were also detected during the commercial phase. He gave the following examples: Changes in personnel (including management) Maintenance, repairs, changes to equipment Deviations in the manufacturing process Trends in analytical results Customer complaints Regulatory changesAnd this is precisely why Dr Schönfeld sees ongoing/continued process verification as the ideal means of detecting these anomalies. The aim is also to further develop the process on the basis of the extensive data material.Ongoing/Continued Process Verification replaces routine revalidation, at least in the non-sterile area. For him, an important aspect of Ongoing/Continued Process Verification is an approved plan that describes which process is being considered, the scope and frequency of verifications depending on process knowledge, performance and incremental changes over time in the life cycle.He sees the use of statistics, which are already largely used for product quality review (PQR), as a further expectation of the authorities. However, PQR does not replace ongoing/continued process verification, as it is created relatively late and is also product- rather than process-related.He recommends specifying in the validation master plan that a change control event should always also evaluate the control status of the process. Furthermore, in his opinion, the validation master plan should also specify the number of incremental changes that triggers consideration in the ongoing/continued process verification. He also recommends a rolling review to identify trends and evaluate the control status.An ongoing/continued process verification report should show whether a process is in a controlled state or not and what additional measures (e.g. monitoring, sampling) may be necessary.With regard to continued process verification in the US FDA Process Validation Guidance, he concluded: Different wording between EU and US but the same life cycle approach. Finally, Franz Schönfeld described three GMP deficiencies in process validation from his inspection practice.ECA members can view the entire presentation in the members' area under Video Presentations.

来源:ECA GMP News · gmp-compliance.org